Jakavi is an anti-cancer medicine that contains the active substance Ruxolitinib. It is used in the treatment of myelofibrosis (cancer of bone marrow), polycythaemia vera (cancer of the blood), and graft-versus-host disease (GVHD), a complication of hematopoietic stem-cell transplant. It belongs to the group of medicines called kinase inhibitors, works by inhibiting the signaling of cytokines and growth factors which are essential for the formation of cellular components of blood and immune function. As a result, it helps slow down the multiplication and spread of cancer cells.

Inform the doctor if you have high blood pressure, aneurysm (enlargement and weakening of blood vessel wall), history of blood clots in your arteries, heart diseases (such as congestive heart failure, heart attack), kidney diseases (such as mild/moderate/severe renal impairment), and/or liver diseases (such as mild/moderate/severe hepatic impairment).

Inform the doctor about all your medical conditions, prescription and non-prescription drugs, vitamin supplements, herbal medications, since Jakavi can interact with them.

Jakavi can cause an allergic reaction in some patients therefore it is necessary to read the complete composition list and consult the doctor in case of any ingredient that induces allergies. Consult the doctor if you are planning, on a pregnancy or breastfeeding. It is advisable to avoid driving and operating heavy machinery during the course of Jakavi.